Insmed, Inc. (NASDAQ:INSM - Get Free Report) has received an average rating of "Moderate Buy" from the seventeen ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $139.8571.
Several research analysts have recently issued reports on the stock. Truist Financial upped their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Mizuho increased their price objective on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Guggenheim increased their price objective on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a report on Monday, September 8th. Jefferies Financial Group increased their price objective on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Finally, Wells Fargo & Company increased their price objective on Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a report on Wednesday, September 3rd.
Read Our Latest Report on Insmed
Insmed Price Performance
Shares of NASDAQ:INSM traded up $1.08 during trading on Friday, hitting $145.86. 1,835,983 shares of the company were exchanged, compared to its average volume of 1,991,598. The business's 50 day moving average is $123.24 and its 200-day moving average is $93.72. The company has a market capitalization of $30.83 billion, a P/E ratio of -25.54 and a beta of 0.97. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed has a 1-year low of $60.40 and a 1-year high of $149.08.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities analysts forecast that Insmed will post -4.56 earnings per share for the current year.
Insiders Place Their Bets
In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 335,097 shares of company stock valued at $39,721,648 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Insmed
Large investors have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. lifted its position in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares in the last quarter. Elequin Capital LP bought a new position in Insmed in the 4th quarter valued at about $28,000. ORG Partners LLC increased its stake in Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 196 shares during the last quarter. Hilltop National Bank purchased a new stake in Insmed in the 2nd quarter valued at about $28,000. Finally, FNY Investment Advisers LLC purchased a new stake in Insmed in the 2nd quarter valued at about $33,000.
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More

Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.